Equity Details
Price & Market Data
Price: $5.90
Daily Change: -$0.14 / 2.37%
Daily Range: $5.74 - $6.09
Market Cap: $40,142,856
Daily Volume: 92,797
Performance Metrics
1 Week: -5.95%
1 Month: 8.13%
3 Months: -11.06%
6 Months: -56.51%
1 Year: -63.55%
YTD: -54.32%
About Plus Therapeutics, Inc. (PSTV)
Explore the fundamentals of Plus Therapeutics, Inc. (PSTV). The stock is at 5.90, exhibiting a daily change of -$0.14 / 2.37%. Its market capitalization is 40,142,856. Performance metrics cover YTD and all monthly and weekly periods.
Company Details
Employees: 28
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.